What happened with RVMD today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Revolution Medicines is a clinical-stage cancer-drug developer focused on tumors that depend on RAS to grow and survive. Its experimental drugs directly block RAS in its active state, an approach it calls RAS(ON) inhibition. These include daraxonrasib, which targets multiple RAS variants, and zoldonrasib and elironrasib, which target specific mutations.
The company has no approved products or product-sales revenue. It funds development through stock offerings and other financing, including money from Royalty Pharma in exchange for rights to royalties on future daraxonrasib sales and certain zoldonrasib sales. It expects to need additional funding to develop and potentially launch its drugs.
If its drugs receive marketing approval, Revolution Medicines plans to sell them itself in the United States and other regions, potentially using regional partners or distributors. Future sales depend on successful clinical development and approval, doctors prescribing the drugs, and insurers and other payors covering treatment. The company relies on outside manufacturers for all drug production, including planned commercial supplies.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Revolution Medicines’ prospects hinge on RAS-inhibitor trial results and approvals, with privately held Boehringer Ingelheim and Roche/Genentech also important competitors outside this list.
Erasca competes with Revolution Medicines to develop drugs for RAS-driven cancers, with no approved products or revenue as of December 31, 2025. Trial results for its broad RAS inhibitor ERAS-0015 and broad KRAS inhibitor ERAS-4001 are the competitive developments to watch.
BridgeBio Oncology Therapeutics competes directly with Revolution Medicines by developing precision medicines for RAS-driven tumors; neither this development work nor its candidates have produced product-sales revenue. Its BBO-8520, BBO-11818 and BBO-10203 pipeline includes potential combinations for KRAS-mutant tumors, making clinical progress the relevant competitive signal.
Adlai Nortye’s AN9025 competes with Revolution Medicines’ daraxonrasib by blocking active RAS across multiple forms, using the same broad therapeutic mechanism. Watch AN9025’s Phase I results: Adlai Nortye reports stronger potency than a same-mechanism clinical benchmark in preclinical models, not a demonstrated advantage in patients.
Verastem’s licensed KRAS G12D program competes with Revolution Medicines’ zoldonrasib, while Verastem already sells AVMAPKI FAKZYNJA CO-PACK in the United States. That treatment serves adults with KRAS-mutated recurrent low-grade serous ovarian cancer after prior systemic therapy; its sales show commercial activity in a specific KRAS-mutant patient group, rather than results for the competing G12D program.
Amgen both sells LUMAKRAS, a KRAS G12C inhibitor competing with Revolution Medicines’ pipeline, and tests its AMG 193 with Revolution Medicines’ daraxonrasib. Results from the Amgen-sponsored combination trial in second-line pancreatic ductal adenocarcinoma matter directly to daraxonrasib’s development.
Bristol Myers Squibb sells KRAZATI, a KRAS G12C inhibitor competing with Revolution Medicines’ pipeline, but also plans to test its navlimetostat with daraxonrasib. Progress in that BMS-sponsored pancreatic ductal adenocarcinoma trial would also inform daraxonrasib’s prospects as a combination treatment.
Tango Therapeutics’ combination-trial results directly inform Revolution Medicines’ pipeline because Tango tests its PRMT5-blocking drug vopimetostat with daraxonrasib or zoldonrasib. The trial focuses on pancreatic ductal adenocarcinoma or lung cancer with MTAP depletion and RAS mutations, so results apply to that genetically defined patient group.
Summit Therapeutics and Revolution Medicines share the outcome of trials combining Summit’s ivonescimab with daraxonrasib, elironrasib and zoldonrasib. Ivonescimab is designed to block PD-1 and VEGF signaling; safety and efficacy in multiple solid-tumor settings are the readouts to watch for these RAS-drug combinations.
Royalty Pharma funds Revolution Medicines in exchange for a share of future worldwide net sales of daraxonrasib and, if approved for the same indication or a subset of it, zoldonrasib—contractual payments called synthetic royalties. Its returns therefore depend on these drugs’ commercial success, while Revolution Medicines receives funding but gives up part of future sales.
Elicio Therapeutics competes for pancreatic and other mutant-KRAS cancer treatment with vaccines rather than Revolution Medicines’ direct RAS-blocking drugs, including a strategy studied after surgery and chemotherapy. Watch its Phase II ELI-002 7P study in mutant-KRAS pancreatic ductal adenocarcinoma for progress in this different treatment approach.
Silexion Therapeutics targets G12D/V pancreatic cancers also addressed by Revolution Medicines, but initially focuses on the narrower group with non-resectable locally advanced disease. Its SIL204 aims to stop mutant KRAS protein production by breaking down its RNA instructions, rather than blocking the protein; watch progress in this specific pancreatic-cancer setting.
Fed Interest Rate Decision
Revolution Medicines’ rate-sensitive cash holdings can earn more or less interest as rates change, while rates also affect the cost of any term loans it draws.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher rates could lift interest earned on the company’s cash and marketable securities, but would also make any drawn term loans more expensive because their rate is tied to SOFR, a benchmark borrowing rate.
If it comes in below expectations
Lower rates could reduce interest earned on the company’s cash and marketable securities, but would also make any drawn term loans less expensive because their rate is tied to SOFR, a benchmark borrowing rate.
Revolution Medicines, Inc. earningsThis company
Revolution Medicines has no product-sales revenue, so its report shows how much it is spending to advance RAS inhibitors and prepare for commercialization, and how long its cash can support that work.
Read research and development spending and cash used in operations alongside cash and marketable securities, with particular attention to spending on daraxonrasib. Rising investment with a substantial cash reserve would show the company is funding its lead candidate; faster cash use without matching investment or program progress would mean it may need funding sooner or slow development and launch preparations.
